Mr Glyn Allsop

Integrated Solutions from Research to Commercialisation.

Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.

Our vast range of services include:

Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory. 


API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.

Pharmaceutical Development:  Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.


Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.


Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.


Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.


Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.


 Almac – Partnering to Advance Human Health™

Company Type
Almac Group

Dr Tarig Arbab

Through the novel application of gap analysis methods in disease biotechnology, SST develops medications that serve as biochemical prostheses that bridge broken reaction pathways, create a normal physiological environment and programme the body to build a natural resistance to the disease. Unlike conventional treatments that act to directly suppress diseases rapidly often with adverse side- effects, SST’s products are designed to gradually correct genetic faults and biochemical mistakes that underlie these diseases. 

SST has been developing a series of patented pharmaceutical and medical device technologies and has found commercial success in its product, Amzylite F1.2, the first of its many upcoming diabetic oral medications.

Saccharides Science and Technology
Executive Director 

Ms Lin Bateson United Kingdom

BioPartner.co.uk is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees.

Ms Lin Bateson
BioPartner.co.uk
Exec Director 

Mr Philip Berry

Integrated Solutions from Research to Commercialisation.

Almac is a financially secure, privately owned organisation with over 3,300 employees located within the US and UK. Over 600 companies worldwide, including all the market leaders, use our services, testament itself to the quality, innovation and efficiency of our business as proven over the past 30+ years.

Our vast range of services include:

Biomarker Discovery & Development: Pre-clinical biomarker discovery, through to full companion diagnostic development and clinical test delivery from our CLIA laboratory. 


API Services & Chemical Development: Services for all stages of drug development for small molecules, potent and cytotoxic compounds and peptides.

Pharmaceutical Development:  Developing clinical candidates into an optimum formulation and manufacturing drug product for all phases of clinical trial supply.


Analytical Services: Delivering comprehensive solutions supporting drug substance and product development programmes.


Clinical Trial Supply: Offering over 20 years experience in clinical supply, packaging, distribution and management.


Clinical Technologies: Providing interactive voice and web response technologies, flexible solutions for patient enrollment, electronic PROs and adaptive trials.


Commercial Services: Services for all drug products from manufacturing, testing and packaging to end-user distribution.


 Almac – Partnering to Advance Human Health™

Company Type
Almac Group

Dr Richard Broadhead

OET Ltd is a biotechnology company and centre of excellence for baculovirus based recombinant protein expression. OET provides protein expression products, services, consultancy and training to pharmaceutical and biotech companies and academic institutions. OET is also carrying out an extensive R&D programme.

Website:
www.oetltd.co.uk
Company Type
Dr Richard Broadhead
Oxford Expression Technologies
Sales & Marketing Manager 

Dr Martin Buckland

Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.

Oncology Focused

We are a leader in innovative small-molecule therapeutics with particular expertise in fragment-based drug discovery, the most important advance in discovery chemistry in the last 20 years. Our primary areas of focus are oncology and hematology.

Financially Strong

We are a publicly traded pharmaceutical company with strong cash reserves and royalty revenues from the sales of our product DACOGEN®. In addition, our partnerships could deliver nearly $2 billion in product milestones plus royalties.

Website:
www.astx.com
Company Type
Dr Martin Buckland
Astex Pharmaceuticals

Mr Alastair Carrington

Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.  The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org

Mr Alastair Carrington
BIA (UK BioIndustry Association)

Dr Karen Chandler-Smith

Founded over 20 years ago at the infancy of biotechnology, the BIA is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.  The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org

Dr Karen Chandler-Smith
BIA (UK BioIndustry Association)

Dr Paul Clewlow

Sygnature Discovery is a leading United Kingdom-based provider of integrated drug discovery services to the global pharmaceutical industry. Key areas of expertise include medicinal and synthetic chemistry, computational chemistry and bioscience. Sygnature´s team of more than 50 industry-experienced scientists add considerable value to our clients´ programmes by undertaking key elements of the drug discovery process, such as hit finding, hit-to-lead, lead optimisation and complete integrated drug discovery projects.

Services on offer at Sygnature include:

  • Medicinal Chemistry
  • Synthetic Chemistry
  • Computational Chemistry
  • Bioscience (in vitro biology and screening)
  • Arrays and Libraries
  • Process and Scale-up Chemistry
  • ADME/Toxicology (via a strategic alliance with Cyprotex Discovery)
Dr Paul Clewlow
Sygnature Discovery

Mr Paul Cronin

Diamond Pharma Services is a leading technical and scientific consulting group serving the biotechnology and pharmaceutical industry. Our emphasis is on the following areas:

  • Regulatory Affairs: From Product Concept to Registration and Beyond
  • Product Development: Nonclinical, CMC and Clinical Aspects
  • Pharmacovigilance: Clinical trial (Phase I-IV), Post-Marketing and QPPV Services
  • Compliance: GLP, GMP, GCP and QP Services
  • Patient Information Leaflet Testing: Over 120 Tested with 100% Positive Agency Feedback

Our clients range from virtual start-up companies to the largest multi-national corporations. Our expertise includes products of recombinant DNA and hybridoma technology, nucleotide based products (RNA and DNA), synthetic peptides, chemical entities (innovative and generic), vaccines (therapeutic and prophylactic), blood products and advanced therapy medicinal products (gene therapy products).

We have sophisticated and well-equipped office facilities and a state-of-the-art IT system. Our IT system includes a fully validated in-house eCTD system (Extedo) and safety database (ARISg). The company was founded in 2005 by Dr. Maureen Graham, formerly Director of Regulatory Affairs at Amgen. Our specialised team of more than 24 professionals includes those with a broad and varied industry experience and former regulators, offering both breadth and depth of expertise, from which our clients can benefit.

Diamond Pharma Services